Your browser doesn't support javascript.
loading
The Influence of Branched-Chain Amino Acid Supplementation on Fatigue and Tryptophan Metabolism After Acute and Chronic Exercise in Older Adults: Protocol for a Pilot Randomized Controlled Trial.
Robbins, Ronna N; Cortes, Tiffany; O'Connor, Jason C; Jiwani, Rozmin; Serra, Monica C.
Afiliação
  • Robbins RN; Department of Nutrition and Food Science, Texas Woman's University, Denton, TX, United States.
  • Cortes T; South Texas Veterans Health Care System, Geriatric Research Education and Clinical Center, San Antonio, TX, United States.
  • O'Connor JC; South Texas Veterans Health Care System, Geriatric Research Education and Clinical Center, San Antonio, TX, United States.
  • Jiwani R; Sam & Ann Barshop Institute for Longevity & Aging Studies, Department of Medicine, University of Texas Health Health Science Center San Antonio, San Antonio, TX, United States.
  • Serra MC; South Texas Veterans Health Care System, San Antonio, TX, United States.
JMIR Res Protoc ; 12: e52199, 2023 Nov 01.
Article em En | MEDLINE | ID: mdl-37910166
ABSTRACT

BACKGROUND:

Fatigue is a strong predictor of negative health outcomes in older adults. Kynurenine, a metabolite of tryptophan, is strongly associated with fatigue. Reductions in fatigue are observed with exercise; however, exercise training does not completely alleviate symptoms. Branched-chain amino acids (BCAAs) have been shown to have advantageous effects on exercise performance and compete with kynurenine for transport into the central nervous system. Thus, the combination of BCAA and exercise may exert synergized effects of mental and physical fatigue. Therefore, we hypothesize that BCAA added to exercise will shift kynurenine metabolism toward enhanced synthesis of kynurenic acid, thereby reducing fatigue.

OBJECTIVE:

This randomized, double-blind, placebo-controlled trial aims to compare the effects of acute (approximately 45 min) and chronic (8 wk) exercise with and without BCAA supplementation on mental and physical fatigue and assess whether the hypothesized outcomes are modulated by changes in kynurenine metabolism in 30 older adults (n=15, 50% per group).

METHODS:

Older adults (aged 60-80 y) who do not exercise >2 days per week and self-report fatigue (≥3 on a scale of 1-10) will be recruited. Participants will be randomized to either the exercise+BCAA group or exercise+placebo group. Participants will engage in high-volume, moderate-intensity, whole-body exercise training (aerobic and resistance exercise; either in-person or web-based sessions) 3 times per week for 8 weeks. In addition, participants will consume daily either 100 mg/kg body weight of BCAA (211 leucineisoleucinevaline) or placebo (maltodextrin) throughout the 8-week intervention. BCAA and placebo powders will be identical in color and dissolved in 400 mL of water and 2.5 g of a calorie-free water flavor enhancer. Muscle biopsies will be collected before and after the intervention after a 12-hour fast to examine changes in the biomarkers of tryptophan metabolism and inflammation. Our primary outcomes include changes in mental and physical fatigue and metabolism after the 8-week exercise training between the 2 groups. Mental and physical fatigue will be measured before and after the intervention. Mental fatigue will be subjectively assessed through the completion of validated questionnaires. Physical fatigue will be measured by isometric handgrip, 1-repetition maximum, chair rise, 400-meter walk, and cardiopulmonary exercise tests.

RESULTS:

The study was funded in March 2022, with an anticipated projected data collection period lasting from January 2023 through December 2023.

CONCLUSIONS:

The discovery that kynurenine concentrations are associated with fatigue and are responsive to BCAA supplementation during exercise training could have important implications for the development of future interventions, both lifestyle and pharmacologic, to treat fatigue in older adults. TRIAL REGISTRATION ClinicalTrials.gov NCT05484661; https//www.clinicaltrials.gov/study/NCT05484661. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/52199.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article